Decoy Therapeutics (NASDAQ:DCOY) and AngioSoma (OTCMKTS:SOAN) Head to Head Analysis

Decoy Therapeutics (NASDAQ:DCOY) and AngioSoma (OTCMKTS:SOAN) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares Decoy Therapeutics and AngioSoma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
AngioSoma	N/A	N/A	-1,245.34%

Earnings & Valuation

This table compares Decoy Therapeutics and AngioSoma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52 million	($106.90)	-0.04
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A

Institutional & Insider Ownership

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of AngioSoma shares are owned by institutional investors. 0.3% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Decoy Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, AngioSoma has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Decoy Therapeutics and AngioSoma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1	0	1	0	2.00
AngioSoma	0	0	0	0	0.00

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 563.72%. Given Decoy Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Decoy Therapeutics is more favorable than AngioSoma.

Summary

Decoy Therapeutics beats AngioSoma on 7 of the 9 factors compared between the two stocks.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.